<DOC>
	<DOCNO>NCT00843154</DOCNO>
	<brief_summary>The purpose study determine effect Candesartan , daily ( QD ) , add ongoing chronic heart disease therapy measure brain natriuretic peptide patient chronic heart failure .</brief_summary>
	<brief_title>Efficacy Candesartan Brain Natriuretic Peptide Levels Subjects With Chronic Heart Failure</brief_title>
	<detailed_description>Chronic heart failure significant increase cause morbidity mortality , account current yearly prevalence 5 million 5-year survival near 50 % US . In addition , chronic heart failure still fourth cause hospitalization US Western country , lead cause hospitalization patient age 65 . Newer pharmacological agent non pharmacological therapeutic tool increasingly introduce improve outcome patient chronic heart failure . In past two decade , several large randomize control clinical trial revolutionize management prognosis patient chronic heart failure . The recommended drug treatment decrease mortality morbidity chronic heart failure base angiotensin convert enzyme-inhibitors , beta-blockers aldosterone antagonist ( limit severe patient ) , detailed late European Society Cardiology guideline . The use digitalis diuretic still role . Orally active angiotensin II type I receptor blocker represent new class agent offer alternative method renin-angiotensin system blockade . Their effect hemodynamics , neuroendocrine activity exercise tolerance patient chronic heart failure consider similar exhibit angiotensin convert enzyme -inhibitors , still remain fully elucidate whether angiotensin II type I receptor blocker offer advantage efficacy , safety , compare angiotensin convert enzyme -inhibitors . Brain Natriuretic Peptide strongly related severity increase cardiovascular event patient chronic heart failure . Recent data show angiotensin II receptor blocker reduce level Brain Natriuretic Peptide , though data available patient preserve left ventricular systolic function . Candesartan selective angiotensin II type I receptor blocker , study evaluate effect maximum tolerate dose Candesartan add ongoing standard therapy measuring change brain natriuretic peptide biomarker use assessment chronic heart failure .</detailed_description>
	<mesh_term>Heart Failure</mesh_term>
	<mesh_term>Candesartan</mesh_term>
	<mesh_term>Candesartan cilexetil</mesh_term>
	<mesh_term>Natriuretic Peptide , Brain</mesh_term>
	<criteria>Females childbearing potential sexually active must agree use adequate contraception , neither pregnant lactating Screening throughout duration study . Stable , symptomatic New York Heart Association IIIV Chronic Heart Failure Left Ventricular Ejection Fraction less great great equal 40 % treated standard therapy include Angiotensin Converting Enzymeinhibitors and/or betablockers . Patients Left Ventricular Ejection Fraction great equal 40 % hospitalized cardiovascular event past 12 month . History prior treatment AngiotensinReceptor Blockers within two week first . Severe malignant hypertension ( Systolic Blood Pressure / Diastolic Blood Pressure great 180/110 mmHg ) . Symptomatic hypotension . Acute myocardial infarction within one month first visit . Stroke transient ischemic attack within one month first visit . Percutaneous transluminal coronary angioplasty coronary artery bypass graft within one month first visit . Hemodynamically relevant arrhythmia . Implant pacemaker , cardiac resynchronization therapy cardioverters within 6 month prior randomization . Hemodynamically relevant cardiac valvular defect . Constrictive pericarditis active myocarditis . Likelihood cardiac surgical intervention ( type ) overall treatment period . Evidence angina pectoris previous month . Poorly control diabetes mellitus ( glycemia great 140mg/mL glycosylated hemoglobin great 8 % obtain within three month study initiation ) . Untreated thyroid dysfunction . Renal artery stenosis . Angioedema etiology . Significant liver ( aspartate aminotransferase , alanine aminotransferase , total bilirubin alkaline phosphatase great twice upper limit normal range ) renal ( serum creatinine great 2.0 mg/dL serum potassium great 5.0 mmol/L ) impairment . Anemia etiology ( define hemoglobin level less 10.5 g/dL ) clinically relevant hematological disease . Any disease malabsorption . Presence noncardiac ( e.g . cancer ) disease likely significantly ( i.e . 1 year randomization ) shorten life expectancy . History chronic alcohol drug/substance abuse , presence condition potentially able affect study subject ' compliance . Known allergy , sensitivity intolerance study drug and/or study drug ' formulation ingredient . Participation another trial month precede study entry .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2010</verification_date>
	<keyword>Natriuretic Peptide , Brain</keyword>
	<keyword>Biological Markers</keyword>
	<keyword>Biomarkers</keyword>
	<keyword>Cardiac Failure</keyword>
	<keyword>Congestive Heart Failure</keyword>
	<keyword>Heart Decompensation</keyword>
	<keyword>Drug Therapy</keyword>
</DOC>